We would like to add to the discussion of the article by Schwab et al. (2011) , reporting the long-term effect of betaine supplementation in young healthy subjects.
We are surprised that the authors studied young healthy subjects when the title implies that they were investigating the effect of betaine on risk factors associated with the metabolic syndrome. Features of the metabolic syndrome have been associated with low plasma betaine concentrations and elevated urinary betaine excretion, with the effect being more pronounced in males than in females (Lever et al., 2005; Konstantinova et al., 2008) . It has therefore been proposed that betaine insufficiency is a common feature of the metabolic syndrome (Lever and Slow, 2010) . Possible causes are excessive urinary betaine loss and a reduced ability to endogenously produce betaine by choline oxidation because of mitochondrial dysfunction. Thus, metabolic syndrome patients could benefit from betaine supplementation. The results, obtained in a young, healthy, predominantly female and probably betaine-replete population, are not a reliable guide to the likely benefits of betaine supplementation for patients, and thus the reference to the metabolic syndrome in the title of the paper is incongruous.
The authors confirm previous observations that increasing habitual betaine intake increases fasting plasma betaine concentrations to a new set-point (Atkinson et al., 2009; Price et al., 2010) . This occurs within days of increasing betaine intake, with a minimal elevation in urinary betaine excretion relative to the dose supplied (Atkinson et al., 2009) . The authors report a significant increase in betaine excretion in the betaine-supplemented group, but do not discuss that less than 4% of the dose is excreted. As an important intracellular osmolyte, betaine is actively accumulated in most tissues to concentrations higher than the circulation (Lever and Slow, 2010) . These tissue stores must have been saturated within days, if not hours; therefore, well over 90% of the supplemented betaine was being metabolised. Yet, interestingly, there was no significant effect on plasma homocysteine. The authors discuss some reasons for this lack of an effect, but we observe that it is possible to methylate large amounts of homocysteine with only a minimal effect on plasma concentrations. In normal metabolism, homocysteine is either catabolised or methylated to methionine. The cellular response to high levels of methionine is to demethylate it to homocysteine via the action of glycine N-methyltransferase, thus generating a futile cycle. This cycling is probably the main reason for the minimal change in circulating homocysteine. Others have reported significant reductions in homocysteine in response to more modest supplementation (Olthof et al., 2003; Price et al., 2010) , which further supports our conclusion that the study population was betaine replete and inappropriate for assessing the effect on metabolic syndrome patients. Schwab et al. (2011) confirm the safety of long-term betaine supplementation. The minimal effect on plasma lipids is interesting in view of suggestions that the effect of betaine on plasma lipids is dose dependent (Konstantinova et al., 2008; Atkinson et al., 2009; Price et al., 2010) . There are still many questions that need to be resolved.
